Literature DB >> 28948063

Fetal Thoracoamniotic Shunting in a Case of Congenital Pulmonary Airway Malformations with Hydrops Fetalis.

Hayase Nitta1, Yusuke Taira1, Tadatsugu Kinjo1, Yukiko Chinen1, Hitoshi Masamoto1, Naoya Sanabe2, Hideki Goya3, Tomohide Yoshida3, Rika Sugibayashi4, Masahiro Sumie4,5, Seiji Wada4, Haruhiko Sago4, Yoichi Aoki1.   

Abstract

Aim  We report a case of congenital pulmonary airway malformation (CPAM) with hydrops in which the fetus underwent thoracoamniotic shunting. Case Report  A 40-year-old (G1P1) woman was diagnosed with a macrocystic CPAM. Thoracoamniotic shunting was performed at 19 weeks of gestation but not well drained and was successfully performed again at 23 weeks. However, the CPAM volume ratio, abdominal circumference, and amniotic fluid index started increasing from 28 weeks and hydrops worsened. The insufficient shunting and the fetal cardiac failure had to be considered. At 32 weeks, a male infant with general edema and massive ascites was born weighing 3,362 g (+4.79 SD) with Apgar scores of 2 and 4. The infant was intubated and high-frequency oscillation and nitric oxide therapies were instituted. The resection of CPAM was performed on day 2. Nasal continuous positive airway pressure was instituted on day 16. The infant was discharged and prescribed with home oxygen therapy (HOT) on day 65. The infant was able to leave the HOT at 30 months and is currently 34 months of age in good condition. Conclusion  Fetal thoracoamniotic shunting may be life-saving in CPAM complicated by hydrops and that this treatment might be sufficient to cure the child.

Entities:  

Keywords:  CPAM; high-frequency oscillation; hydrops fetalis; nitric oxide; thoracoamniotic shunting

Year:  2017        PMID: 28948063      PMCID: PMC5610044          DOI: 10.1055/s-0037-1606830

Source DB:  PubMed          Journal:  AJP Rep        ISSN: 2157-7005


Congenital pulmonary airway malformation (CPAM) of the lung, also known as congenital cystic adenomatoid malformation, is a rare abnormality (1 out of every 15,000 live births), which is easily diagnosed by prenatal ultrasonography. 1 2 Very large lesions of CPAM carry a significant risk of causing both pulmonary hypoplasia due to compression of lung tissue 3 and fetal hydrops, probably due to impaired cardiac function as a result of mediastinal shift and compression of the vena cava or cardiac tamponade. The prognosis is markedly worsened if hydrops develops, which has been reported in as many as 14 to 30% of the cases referred to fetal therapy centers. 4 5 6 CPAM volume ratio (CVR) was calculated preoperatively following the publication of this predictor in 2002 7 and has been proposed as an index to predict the development of hydrops in cases where this condition exists. If the CVR is more than 1.6, the risk of hydrops is approximately 75%. Fetal thoracoamniotic shunting was offered in the case of macrocystic lesions with fetal hydrops or signs of evolving hydrops such as ascites, and lesions that were very large (CVR >1.6), rapidly increasing in size, or were associated with polyhydramnios. 8 Subsequently, it was clear that in these cases, fetuses can be successfully treated with the much less invasive approach of thoracoamniotic shunting. A systematic review revealed an improved survival rate of 62% (15 of 24) in treated hydropic fetuses versus 3% (1 of 33) in the untreated ones (odds ratio, 19.28; 95% confidence interval, 3.7–101). 9 In a recent review of a total of 110 fetuses with CPAM treated with thoracoamniotic shunting between 1987 and 2016, the survival rate was 77% (53 of 69) for hydropic and 90% (37 of 41) for nonhydropic fetuses. 10 We report a case of CPAM (macrocystic type, Stocker type 1) of the right lung with hydrops fetalis in which the fetus underwent thoracoamniotic shunting.

Case Report

A 40-year-old (G1P1) woman, in her second pregnancy after a cesarean section due to a weak pain that impeded a vaginal delivery, was referred to the University of the Ryukyus Hospital at 19 weeks of gestation for the evaluation of a fetus with a lesion of the right lung. An ultrasound examination revealed a 39 × 37 × 49-mm sized monocystic lesion of the right lung. The heart was shifted to the left, and the amniotic fluid index (AFI) was 9.14 cm. Magnetic resonance imaging (MRI) revealed fetal ascites and subcutaneous edema of the fetal head ( Fig. 1 ). The presentations were consistent with a macrocystic CPAM, Stocker type 1, and the CVR was 1.95.
Fig. 1

Magnetic resonance imaging at 19 weeks of gestation shows large cystic mass in the right lung, fetal ascites, and subcutaneous edema of the fetal head (arrows). CPAM, congenital pulmonary airway malformation.

Magnetic resonance imaging at 19 weeks of gestation shows large cystic mass in the right lung, fetal ascites, and subcutaneous edema of the fetal head (arrows). CPAM, congenital pulmonary airway malformation. Fetal therapy was considered owing to the large CVR, severe mediastinal shift, polyhydramnios, and ascites. Thoracoamniotic shunting was performed at 19 weeks of gestation but not well drained because of increased CVR thereafter. Shunting was successfully performed again at 23 weeks with reduction of the cystic mass; the procedure was done at the National Center for Child Health and Development Hospital (Tokyo, Japan). However, the CVR, abdominal circumference (AC), and AFI started increasing from 28 weeks of gestation. The CVR was 2.6; AC was 22 mm with massive fetal ascites and worsened subcutaneous edema; AFI was 32 cm at 30 weeks of gestation ( Fig. 2 ); and premature rupture of the membrane occurred. Thereafter, the CVR repeatedly increased and decreased. The insufficient shunting and the fetal cardiac failure had to be considered. Fetal well-being was secured under close cardiotocography and biophysical profile scoring monitoring. At 32 4/7 weeks of gestation, after awaiting fetal maturation, an elective cesarean section was performed. A male infant with general edema and massive ascites was born weighing 3,362 g (+4.79 SD) with Apgar scores of 2 and 4.
Fig. 2

Magnetic resonance imaging at 31 weeks of gestation shows marked hydrops fetalis and polyhydramnios.

Magnetic resonance imaging at 31 weeks of gestation shows marked hydrops fetalis and polyhydramnios. The infant was intubated immediately, surfactant was administered, and 40 mL of ascites was removed. Ten minutes after birth, high-frequency oscillation and nitric oxide therapies were instituted as supportive care for stabilizing the infant because of profound persistent pulmonary hypertension. The resection of CPAM (right middle lobectomy) was uneventfully performed on day 2. The closure of PDA was observed by indomethacin administration on day 12. Extubation was performed, and nasal continuous positive airway pressure was instituted on day 16. The infant was discharged and prescribed with home oxygen therapy (HOT) on day 65. No other anomaly was observed. The infant was able to leave the HOT at 30 months and is currently 34 months of age with good condition.

Discussion

In our case, CPAM was diagnosed in the fetus at 19 weeks of gestation by ultrasonography and MRI. As the role of thoracoamniotic shunting in macrocystic lung lesions associated with hydrops is well accepted, 8 9 10 thoracoamniotic shunting was performed soon after the diagnosis of CPAM with hydrops. After the second shunting, the CVR decreased once, thereafter with repeated increases and decreases. The hydrops and polyhydramnios worsened. Insufficient drainage was considered. One of the arguments for shunting large lesions is the prevention of pulmonary hypoplasia, 3 11 and suggested prognostic markers include size and type of lesion, the presence of mediastinal shift, polyhydramnios, hydrops, and CVR. 7 Our case included all of these; however, atleast mediastinal compression was relieved by the shunting. Hydrops fetalis is defined as a state of excessive fluid accumulation in the extravascular compartment of the fetus, leading to widespread soft-tissue edema and/or collection of fluid in two or more fetal serous body cavities. The association of CPAM and nonimmune fetal hydrops is reported to carry a very poor prognosis for survival. 12 In cases in which the mechanism of hydrops involves high-output cardiac failure 13 in addition to mediastinal compression, 14 the development of hydrops fetalis is probably secondary to cardiac failure due to left-to-left shunting that may occur in the presence of an anomalous systemic artery and venous drainage via pulmonary or systemic veins. 12 We could not find any vascular anomalies in our case. The inferior vena cava occlusion and poor venous return because of mediastinal deviation were considered to be the causes of fetal subcutaneous edema and exacerbation of fetal ascites; however, no obvious cardiac preload was observed in the fetus by ultrasound examination. Repeated increase and decrease in CVR due to an imbalance in the pressure between the pulmonary cyst and excessive amniotic fluid indicated that the shunt functioned to the extent that it did not markedly worsen the fetal cardiac preload. This suggests the possibility that it might improve the prognosis of the fetus. In our case, the fetus had a high risk of neonatal death and resuscitation maneuvers were particularly difficult. As a multidisciplinary group of medical specialists involving obstetricians, perinatologists, radiologists, pediatric surgeons, midwives, and nurses, we had weekly meetings during which decisions concerning management were made. The present case confirms that fetal thoracoamniotic shunting may be life-saving in CPAM complicated by hydrops and that this sole treatment might be sufficient to cure the child.
  14 in total

1.  Direct intrauterine fetal therapy in a case of bronchopulmonary sequestration associated with non-immune hydrops fetalis.

Authors:  C Anandakumar; A Biswas; T M Chua; M Choolani; D Chia; Y C Wong; L Gole
Journal:  Ultrasound Obstet Gynecol       Date:  1999-04       Impact factor: 7.299

2.  Antenatal diagnosis and treatment of fetal bronchopulmonary sequestration.

Authors:  R N Slotnick; J McGahan; L Milio; M Schwartz; D Ablin
Journal:  Fetal Diagn Ther       Date:  1990       Impact factor: 2.587

3.  Fetal intervention for mass lesions and hydrops improves outcome: a 15-year experience.

Authors:  Erich J Grethel; Amy J Wagner; Matthew S Clifton; Raul A Cortes; Diana L Farmer; Michael R Harrison; Kerilyn K Nobuhara; Hanmin Lee
Journal:  J Pediatr Surg       Date:  2007-01       Impact factor: 2.545

Review 4.  Thoracoamniotic Shunts in Macrocystic Lung Lesions: Case Series and Review of the Literature.

Authors:  Magdalena Litwińska; Ewelina Litwińska; Katarzyna Janiak; Anna Piaseczna-Piotrowska; Ewa Gulczyńska; Krzysztof Szaflik
Journal:  Fetal Diagn Ther       Date:  2016-08-05       Impact factor: 2.587

Review 5.  Prenatal diagnosis and management of fetal thoracic lesions.

Authors:  L Morin; T M Crombleholme; M E D'Alton
Journal:  Semin Perinatol       Date:  1994-06       Impact factor: 3.300

Review 6.  In-utero pulmonary drainage in the management of primary hydrothorax and congenital cystic lung lesion: a systematic review.

Authors:  E M Knox; M D Kilby; W L Martin; K S Khan
Journal:  Ultrasound Obstet Gynecol       Date:  2006-10       Impact factor: 7.299

7.  Fetal thoracoamniotic shunting for large macrocystic congenital cystic adenomatoid malformations of the lung.

Authors:  S Schrey; E N Kelly; J C Langer; G A Davies; R Windrim; P G R Seaward; G Ryan
Journal:  Ultrasound Obstet Gynecol       Date:  2012-05       Impact factor: 7.299

8.  Cystic adenomatoid malformation volume ratio predicts outcome in prenatally diagnosed cystic adenomatoid malformation of the lung.

Authors:  Timothy M Crombleholme; Beverly Coleman; Holly Hedrick; Kenneth Liechty; Lori Howell; Alan W Flake; Mark Johnson; N Scott Adzick
Journal:  J Pediatr Surg       Date:  2002-03       Impact factor: 2.545

9.  Fetal lung lesions: management and outcome.

Authors:  N S Adzick; M R Harrison; T M Crombleholme; A W Flake; L J Howell
Journal:  Am J Obstet Gynecol       Date:  1998-10       Impact factor: 8.661

10.  Cystic lung disease in infants and children.

Authors:  J Thomas Stocker
Journal:  Fetal Pediatr Pathol       Date:  2009       Impact factor: 0.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.